Document:

Exhibit 10.3

 

DTHERA
SCIENCES

 

EMPLOYEE AND CONSULTANT SHARE PURCHASE
AGREEMENT

 

 

PLEASE READ THE FOLLOWING LEGENDS
CAREFULLY:

 

DTHERA SCIENCES (THE
“COMPANY”) IS OFFERING TO SELL SHARES OF ITS COMMON STOCK (THE “SHARES”) TO CERTAIN EMPLOYEES AND CONSULTANTS
OF THE COMPANY. THE SHARES BEING OFFERED FOR SALE PURSUANT TO THIS AGREEMENT INVOLVE A HIGH DEGREE OF RISK AND, THEREFORE, SHOULD
BE CONSIDERED EXTREMELY SPECULATIVE. THEY SHOULD NOT BE PURCHASED BY PERSONS WHO CANNOT AFFORD THE POSSIBILITY OF THE LOSS OF THEIR
ENTIRE INVESTMENT.

 

THIS AGREEMENT INVOLVES
SUBSTANTIAL RISK, INCLUDING, BUT NOT LIMITED TO, RISKS ARISING FROM THE COMPANY’S LACK OF OPERATING HISTORY, FINANCIAL ASSETS
AND REVENUES, COMPETITION, LACK OF DIVERSIFICATION, AND THE ABSENCE OF A MARKET FOR AND RESTRICTIONS ON THE TRANSFERABILITY OF
THE SHARES.

 

THIS AGREEMENT OF THE
COMPANY IS OFFERED PURSUANT TO AN EXEMPTION FROM REGISTRATION WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION (“SEC”)
AND APPLICABLE STATE SECURITIES COMMISSIONS. HOWEVER, THE SECURITIES AND EXCHANGE COMMISSION AND SUCH STATE COMMISSIONS HAVE NOT
MADE AN INDEPENDENT DETERMINATION THAT THE SHARES OFFERED HEREBY ARE EXEMPT FROM REGISTRATION. IN ADDITION, THE SHARES HAVE NOT
BEEN APPROVED OR DISAPPROVED BY THE SECURITIES AND EXCHANGE COMMISSION OR BY ANY SUCH STATE SECURITIES COMMISSION, NOR HAVE ANY
SUCH AGENCIES PASSED UPON THE ACCURACY OR ADEQUACY OF THIS AGREEMENT. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.

 

PROSPECTIVE INVESTORS
ARE NOT TO CONSTRUE THE CONTENTS OF THIS AGREEMENT OR ANY PRIOR OR SUBSEQUENT COMMUNICATIONS FROM ANY OF OUR MANAGEMENT, AGENTS,
REPRESENTATIVES OR EMPLOYEES, AS INVESTMENT, LEGAL, TAX, OR ACCOUNTING ADVICE. THE PURCHASER OF THE SHARES SHOULD CONSULT ITS OWN
ATTORNEY, ACCOUNTANT AND OTHER PROFESSIONAL ADVISORS AS TO LEGAL, TAX, ACCOUNTING AND OTHER RELATED MATTERS CONCERNING THE PURCHASE
OF THE SHARES.

 

ANY REPRODUCTION OR
DISTRIBUTION OF THIS AGREEMENT, IN WHOLE OR IN PART, OR THE DIVULGENCE OF ANY OF ITS CONTENTS, WITHOUT OUR PRIOR WRITTEN CONSENT,
IS STRICTLY PROHIBITED.

 

THE SHARES OFFERED
FOR SALE UNDER THIS AGREEMENT ARE OFFERED SUBJECT TO WITHDRAWAL, CANCELLATION OR MODIFICATION OF THE OFFERING WITHOUT PRIOR NOTICE
TO THE PURCHASER PURSUANT TO THE TERMS OF THIS AGREEMENT; AND TO CERTAIN OTHER CONDITIONS SPECIFIED HEREIN. THE COMPANY RESERVES
THE RIGHT TO ACCEPT OR REJECT ANY AGREEMENT, IN WHOLE OR IN PART, FOR ANY REASON OR NO REASON.

 

THE SHARES ARE SUBJECT
TO RESTRICTIONS ON TRANSFERABILITY AND RESALE AND MAY NOT BE TRANSFERRED OR RESOLD EXCEPT AS PERMITTED UNDER THE SECURITIES ACT,
THE APPLICABLE STATE SECURITIES LAWS AND THE APPLICABLE LAWS OF ANY OTHER RELEVANT JURISDICTION PURSUANT TO REGISTRATION OR EXEMPTION
THEREFROM. IN ADDITION, THE SHARES OFFERED HEREUNDER SHALL ALSO BE SUBJECT TO LOCK UP PERIODS AS SET FORTH IN THE AGREEMENT. ACCORDINGLY,
PROSPECTIVE INVESTORS SHOULD BE AWARE THAT THEY WILL BE REQUIRED TO BEAR THE FINANCIAL RISKS OF A PURCHASE OF THE SHARES FOR AN
INDEFINITE PERIOD OF TIME. THERE IS ONLY A LIMITED MARKET FOR THE COMPANY’S COMMON STOCK, AND THERE IS NO OBLIGATION ON THE
PART OF ANY PERSON TO REGISTER THE COMMON STOCK UNDER THE SECURITIES ACT, ANY STATE SECURITIES LAWS OR THE SECURITIES LAWS OF ANY
OTHER JURISDICTION. INVESTMENT IN THE SHARES INVOLVES CERTAIN SIGNIFICANT INVESTMENT RISKS, INCLUDING RISKS OF LOSS OF CAPITAL
OR ENTIRE INVESTMENT.

 

 

 

    	 	1	 

     

    

 

THIS AGREEMENT DOES
NOT CONSTITUTE AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO PURCHASE SHARES IN ANY STATE WHERE IT WOULD BE UNLAWFUL TO MAKE
SUCH AN OFFER OR SOLICITATION AND DOES NOT CONSTITUTE AN OFFER TO SELL OR SOLICITATION TO ANY MEMBER OF THE GENERAL PUBLIC. THIS
AGREEMENT CONSTITUTES AN OFFER ONLY TO THE PERSON OR ENTITY NAMED A PARTY HERETO, AND WHOSE SIGNATURE IS REQUIRED BELOW, AND ONLY
IF IT IS SIGNED ON BEHALF OF THE COMPANY. ANY DISTRIBUTION OF THIS AGREEMENT TO ANY PERSON OR ENTITY OTHER THAN THE PERSON OR ENTITY
NAMED BELOW IS UNAUTHORIZED.

 

IN MAKING AN INVESTMENT
DECISION, THE POTENTIAL INVESTOR MUST RELY ON ITS OWN EXAMINATION OF THE SHARES AND THE COMPANY, AS WELL AS THE TERMS OF THIS AGREEMENT
AND THE COMPANY’S OTHER GOVERNING DOCUMENTS.

 

THIS AGREEMENT CONTAINS
PROPRIETARY AND CONFIDENTIAL INFORMATION OF DTHERA SCIENCES; BY ACCEPTING DELIVERY OF THIS AGREEMENT THE PURCHASER AGREES NOT TO
DISCLOSE ANY INFORMATION CONTAINED HEREIN EXCEPT TO HIS OR ITS LEGAL COUNSEL AND OTHER PROFESSIONAL ADVISORS IN CONNECTION WITH
AN EVALUATION OF THE ADVISABILITY OF INVESTING IN THE COMPANY BY PURCHASING THE SHARES UNDER THIS AGREEMENT.

 

 

 

 

 

 

 

    	 	2	 

     

    

 

EMPLOYEE AND CONSULTANT SHARE PURCHASE AGREEMENT

 

THIS EMPLOYEE AND CONSULTANT
SHARE PURCHASE AGREEMENT (“Agreement”) is made effective as of the _____ day of _____, 2017, by and among
Dthera Sciences, Inc., a Nevada corporation (the “Company”), and the undersigned.

 

RECITALS

 

WHEREAS, the
Company desires to offer to certain of its employees and consultants (each, an “Investor”) the opportunity
to acquire shares of the Company’s common stock (the “Offering”), pursuant to and subject to the
terms as set forth in this Agreement; and

 

WHEREAS, the
Investor wishes to purchase from the Company, and the Company wishes to sell and issue to the Investor, upon the terms and conditions
stated in this Agreement, that number of shares of the Company’s common stock priced at $0.03 per share (the “Common
Stock”); and

 

WHEREAS, the
Company and the Investor agree to be bound by the terms of this Agreement relating to conditions, restrictions, and terms of the
Shares.

 

NOW, THEREFORE,
in consideration of the mutual promises made herein and for other good and valuable consideration, the receipt and sufficiency
of which are hereby acknowledged, the parties hereto agree as follows:

 

1.                 
Purchase and Issuance of the Shares; Restrictions on Resale; Company Repurchase Right.

 

1.1.           
Subject to the terms and conditions of this Agreement, Investor hereby agrees to purchase, and the Company hereby agrees
to sell and issue to the Investor, the number of Shares set forth opposite the Investor’s name on the signature page attached
hereto for a purchase price equal to the product of (x) the number of Shares subscribed for and (y) $0.03 per Share (the “Purchase
Price”).

 

1.2.           
The Purchase Price may be paid as follows:

 

(a)               
payable at Closing by check made payable to the order of “Dthera Sciences” or by wire transfer of immediately
available funds delivered contemporaneously herewith as follows:

 

 

	 	Bank Name: 	Square 1 Bank	 
	 	 	 	 
	 	Bank Address:	406 Blackwell Street, Suite 240	 
	 	 	Durham, NC 27701	 
	 	 	 	 
	 	ABA/Routing #	 	 
	 	Acct #:	 	 
	 	Acct Name: 	EveryStory, Inc.	 
	 	 	 	 
	 	FBO: 	 	 
	 	 	              (Investor
Name)	 

 

1.3.           
The shares of Common Stock purchased pursuant to the Offering are subject to restrictions on their resale as follows:

 

(a)               
One third of the shares of common stock purchased may not be resold until that date which is the earlier of (a) twelve (12)
months from the date that the Company's common stock is accepted for trading on the NASDAQ or another national market, or (b) twenty-four
(24) months from the Closing Date.

 

 

 

 

 

    	 	3	 

     

    

 

(b)              
An additional one third of the shares of common stock purchased may not be resold until that date which is the earlier of
(a) eighteen (18) months from the date that the Company's common stock is accepted for trading on the NASDAQ or another national
market, or (b) thirty (30) months from the Closing Date.

 

(c)               
The final one third of the shares of common stock purchased may not be resold until that date which is the earlier of (a)
twenty-four (24) months from the date that the Company's common stock is accepted for trading on the NASDAQ or another national
market, or (b) thirty-six (36) months from the Closing Date.

 

(d)              
The Board of Directors of the Company has the right, but not the obligation, as determined in the Board’s sole discretion,
to shorten the restrictive periods set forth above for one or more investors in this Offering, including the Investor, on a case
by case basis.

 

1.4.           
The shares of Common Stock purchased pursuant to the Employee Offering will also be subject to a repurchase right (the “Repurchase
Right”) held by the Company that will take effect if the employee or consultant is not employed by or continuing to provide
services to the Company, respectively, at any point prior to the expiration schedule set forth in Exhibit A. The Company's Repurchase
Right will terminate and expire following a term of not less than 5 months from the date of purchase of the Shares or more than
36 months after the date of the purchase of the Shares, to be agreed upon by the Company and the Investor on an individual basis,
as set forth in Exhibit A hereto.

 

(a)               
The Company may exercise the Repurchase Right (as applicable) by paying to the employee any cash paid for the shares of
Common Stock subject to the Repurchase Right and by releasing the employee from any obligation under a promissory note, if applicable,
for the shares of Common Stock subject to the Repurchase Right, or any combination thereof, as applicable.

 

(b)              
Upon the termination of employment with the Company by an employee purchaser, or the termination of providing services to
the Company by a consultant purchaser, such employee or consultant must pay cash for any shares no longer subject to the Repurchase
Right within 15 days of such termination to the extent not fully paid for, or all such shares shall become subject to the Repurchase
Right of the Company.

 

1.5.           
Under no circumstances may the Company require an Investor to purchase shares in the market to satisfy the Company’s
Repurchase Right. The Repurchase Right applies only to shares of the Company’s Common Stock purchased in the Employee Offering
that the Investor holds as of the date the Company exercises the Repurchase Right.

 

1.6.           
Additionally, in the event that there is an “Equity-based Change of Control” in the Company prior
to the expiration of all of the Repurchase Rights as outlined above, any unexpired Repurchase Rights shall expire as of the closing
of the Equity-based Change of Control. For purposes of this Agreement, “Equity-based Change of Control”
shall mean any change in the ownership of more than fifty percent (50%) of the voting capital stock of the Company in one or more
related transactions in which shares of the acquiring entity are exchanged for shares of the Company’s common stock; provided,
however, that in the event that the acquiring entity is a publicly traded entity, such entity shall have the right to impose
similar repurchase rights on any shares issued in exchange for the shares that would otherwise still be subject to the Company’s
Repurchase Right.

 

2.                 
Closing.

 

2.1.           
 The closing shall be held on _____ _____, 2017, at a mutually convenient place as the Company and the Investor mutually
shall agree upon, orally or in writing (which time and place are designated as the “Closing”; the date
of the Closing referred to hereinafter as the “Closing Date”).

 

2.2.           
At Closing, the Company shall deliver, or cause to be delivered promptly thereafter, to Investor (i) a stock certificate
representing the Common Stock purchased by Investor, against delivery to the Company by the Investor of payment therefor by check
or by wire transfer. The stock certificate may also be held in book entry with the transfer agent if the investor so chooses and
will still be considered delivered. The Company and Investor shall also deliver such other documents as are called for herein.

 

 

 

 

    	 	4	 

     

    

 

3.                 
Representations and Warranties of the Company. The following representations and warranties are qualified in their
entirety by the SEC Filings, as defined below. Should any representation or warranty of the Company contain any term that contradicts
anything in the SEC Filings, the SEC Filing shall control. Accordingly, the Company hereby represents and warrants to the Investor
that as of the Closing Date, and subject to the aforementioned qualification that:

 

3.1.           
Organization, Good Standing and Qualification. The Company is a corporation duly organized, validly existing and
in good standing under the laws of the jurisdiction of its incorporation and has all requisite corporate power and authority to
carry on its business as now conducted and to own its properties.

 

3.2.           
Authorization. The Company has full power and authority and has taken all requisite action on the part of the Company,
its officers, directors and stockholders necessary for (i) the authorization, execution and delivery of the Transaction Documents,
(ii) the authorization of the performance of all obligations of the Company hereunder or thereunder, and (iii) the authorization,
issuance (or reservation for issuance) and delivery of the Shares (the “Securities”). The Transaction
Documents constitute the legal, valid and binding obligations of the Company, enforceable against the Company in accordance with
their terms, subject to bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium and similar laws of general applicability,
relating to or affecting creditors’ rights generally.

 

3.3.           
Valid Issuance. The Common Stock and the transaction contemplated hereby have each been duly and validly authorized.
The Shares when issued will be validly issued, fully paid and non-assessable free and clear of all encumbrances and restrictions,
except for restrictions on transfer set forth in the Transaction Documents or imposed by applicable securities laws and except
for those created by the Investor.

 

3.4.           
Consents. The execution, delivery and performance by the Company of the Transaction Documents and the offer, issuance
and sale of the Securities require no consent of, action by or in respect of, or filing with, any Person, governmental body, agency,
or official other than filings that have been or will be made pursuant to applicable state securities laws and post-sale filings
pursuant to applicable state and federal securities laws which the Company undertakes to file within the applicable time periods.
Subject to the accuracy of the representations and warranties of Investor set forth in Section 4 hereof, the Company has taken
and will take all action necessary to exempt (i) the issuance and sale of the Securities, and (ii) the other transactions contemplated
by the Transaction Documents from any provision of the Company’s Articles of Incorporation or Bylaws that is or could reasonably
be expected to become applicable to the Investor as a result of the transactions contemplated hereby. For purposes of this Agreement,
“Person” means an individual, corporation, partnership, limited liability company, trust, business trust,
association, joint stock company, joint venture, sole proprietorship, unincorporated organization, governmental authority or any
other form of entity not specifically listed herein

 

3.5.           
Delivery of SEC Filings; Business. The Company has made available to the Investor through the EDGAR system maintained
by the SEC, true and complete copies of the Company’s most recent Annual Report on Form 10-K for the fiscal year ended December
31, 2016, the Company’s Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2017, and all other reports
filed by the Company pursuant to the Securities Exchange Act of 1934 (collectively, the “SEC Filings”).
Investor is encouraged to carefully review the SEC Filings, including the specific Risk Factors set forth therein. At the time
of filing thereof, the SEC Filings complied as to form in all material respects with the requirements of the Securities Exchange
Act of 1934, as amended (the “1934 Act”) and did not contain any untrue statement of a material fact
or omit to state any material fact necessary in order to make the statements made therein, in the light of the circumstances under
which they were made, not misleading.

 

 

 

 

    	 	5	 

     

    

 

3.6.           
Use of Proceeds. The net proceeds of the issuance and sale of the Common Stock hereunder shall be used by the Company
for working capital and general corporate purposes. Proceeds received pursuant to this Agreement shall be immediately available
to the Company for its use.

 

3.7.           
No Conflict, Breach, Violation or Default. The execution, delivery and performance of the Transaction Documents by
the Company and the issuance and sale of the Securities will not conflict with or result in a breach or violation of any of the
terms and provisions of, or constitute a default under (i) the Company’s Articles of Incorporation or the Company’s
Bylaws, both as in effect on the date hereof (true and complete copies of which have been made available to the Investor through
the EDGAR system), or (ii) any statute, rule, regulation or order of any governmental agency or body or any court, domestic or
foreign, having jurisdiction over the Company or any of its assets or properties, or (iii) any agreement or instrument to
which the Company is a party or by which the Company is bound.

 

3.8.           
Financial Statements. The financial statements included in the SEC Filings present fairly, in all material respects,
the consolidated financial position of the Company as of the dates shown and its consolidated results of operations and cash flows
for the periods shown, and such financial statements have been prepared in conformity with United States generally accepted accounting
principles applied on a consistent basis (“GAAP”) (except as may be disclosed therein or in the notes
thereto). Except as set forth in the financial statements of the Company included in the SEC Filings filed prior to the date hereof,
the Company has not incurred any liabilities, contingent or otherwise, except those incurred in the ordinary course of business,
consistent (as to amount and nature) with past practices since the date of such financial statements, none of which, individually
or in the aggregate, have had or could reasonably be expected to have a material adverse effect on the Company.

 

3.9.           
No Directed Selling Efforts or General Solicitation. Neither the Company nor any Person acting on its behalf has
conducted any general solicitation or general advertising (as those terms are used in Regulation D of the 1933 Act) in connection
with the offer or sale of any of the Securities.

 

3.10.       
Private Placement. Subject to the accuracy of the representations and warranties of Investor set forth in Section
4 hereof, the offer and sale of the Securities to the Investor as contemplated hereby is exempt from the registration requirements
of the 1933 Act.

 

4.                 
Representations and Warranties of the Investor. Investor hereby represents and warrants to the Company that:

 

4.1.           
Authorization. Investor: (i) if a natural person, represents that the Investor has reached the age of 21 and has
full power and authority to execute and deliver this Agreement and all other related agreements or certificates and to carry out
the provisions hereof and thereof; (ii) if a corporation, partnership, or limited liability company or partnership, or association,
joint stock company, trust, unincorporated organization or other entity, represents that such entity was not formed for the specific
purpose of acquiring the Securities, such entity is duly organized, validly existing and in good standing under the laws of the
state of its organization, the consummation of the transactions contemplated hereby is authorized by, and will not result in a
violation of state law or its charter or other organizational or trust documents, such entity has full power and authority to execute
and deliver this Agreement and all other related agreements or certificates and to carry out the provisions hereof and thereof
and to purchase and hold the Securities, the execution and delivery of this Agreement has been duly authorized by all necessary
action, this Agreement has been duly executed and delivered on behalf of such entity and is a legal, valid and binding obligation
of such entity; or (iii) if executing this Agreement in a representative or fiduciary capacity, represents that it has full power
and authority to execute and deliver this Agreement in such capacity and on behalf of the subscribing individual, ward, partnership,
trust, estate, corporation, or limited liability company or partnership, or other entity for whom the Investor is executing this
Agreement, and such individual, partnership, ward, trust, estate, corporation, or limited liability company or partnership, or
other entity has full right and power to perform pursuant to this Agreement and make an investment in the Company, and represents
that this Agreement constitutes a legal, valid and binding obligation of such entity. The execution and delivery of this Agreement
will not violate or be in conflict with any order, judgment, injunction, agreement or controlling document to which the Investor
is a party or by which it is bound.

 

 

 

    	 	6	 

     

    

 

4.2.           
Purchase Entirely for Own Account. The Securities to be received by Investor hereunder will be acquired for Investor’s
own account, not as nominee or agent, and not with a view to the resale or distribution of any part thereof in violation of the
1933 Act, and Investor has no present intention of selling, granting any participation in, or otherwise distributing the same in
violation of the 1933 Act without prejudice, however, to Investor’s right at all times to sell or otherwise dispose of all
or any part of Securities in compliance with applicable federal and state securities laws. Nothing contained herein shall be deemed
a representation or warranty by Investor to hold the Securities for any period of time. Investor is not a broker-dealer registered
with the SEC under the 1934 Act or an entity engaged in a business that would require it to be so registered.

 

4.3.           
Investment Experience. Investor acknowledges that it can bear the economic risk and complete loss of its investment
in the Securities and has such knowledge and experience in financial or business matters that it is capable of evaluating the merits
and risks of the investment contemplated hereby.

 

4.4.           
Disclosure of Information. Investor has had an opportunity to receive all information related to the Company requested
by it and to ask questions of and receive answers from the Company regarding the Company, its business and the terms and conditions
of the offering of the Securities. Investor acknowledges receipt of copies of the SEC Filings via the EDGAR system of the Securities
and Exchange Commission (www.sec.gov). Neither such inquiries nor any other due diligence investigation conducted by Investor shall
modify, amend or affect Investor’s right to rely on the Company’s representations and warranties contained in this
Agreement; provided, Investor shall not rely on representations except those expressly set forth in this Agreement.

 

4.5.           
Restricted Securities; Rule 144 Restriction Period for Common Stock; Additional Restrictions on Resale.

 

(a)               
The Common Stock to be purchased hereunder will not be registered and shall be characterized as “restricted securities”
under the federal securities laws, and under such laws such securities may be resold without registration under the 1933 Act only
in certain limited circumstances. Each certificate evidencing Common Stock to be issued hereunder shall bear a legend in substantially
the following form:

 

THE SECURITIES EVIDENCED BY THIS CERTIFICATE
HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND MAY NOT BE SOLD,
TRANSFERRED, ASSIGNED OR HYPOTHECATED UNLESS THERE IS AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT COVERING SUCH
SECURITIES, THE SALE IS MADE IN ACCORDANCE WITH RULE 144 UNDER THE SECURITIES ACT OR THE ISSUER RECEIVES AN OPINION OF COUNSEL
FOR THE HOLDER OF THESE SECURITIES REASONABLY SATISFACTORY TO THE ISSUER, STATING THAT SUCH SALE, TRANSFER, ASSIGNMENT OR HYPOTHECATION
IS EXEMPT FROM THE REGISTRATION AND PROSPECTUS DELIVERY REQUIREMENTS OF THE SECURITIES ACT. IN ADDITION, THE SECURITIES ARE SUBJECT
TO CERTAIN RESTRICTIONS UNDER THAT CERTAIN INVESTMENT UNIT PURCHASE AGREEMENT ENTERED INTO IN CONNECTION WITH THE ISSUANCE OF THIS
CERTIFICATE.

 

(b)              
The Investor acknowledges and agrees that in addition to the restrictions contractually imposed by this Agreement, as “restricted
securities,” the Common Stock to be purchased by it may not be transferred, hypothecated, sold or otherwise disposed of until
(i) a registration statement with respect to such securities is declared effective under the 1933 Act, or (ii) the Company receives
an opinion of counsel for the holder(s) of such Common Stock, reasonably satisfactory to counsel for the Company, that an exemption
from the registration requirements of the 1933 Act is available. In addition, Investor agrees that Investor will not, for a period
of not less than one (1) year from the date hereof, sell in any public market any Common Stock, or any interest therein, purchased
pursuant to this Agreement.

 

 

 

 

    	 	7	 

     

    

 

4.6.           
Accredited Investor; Non-Accredited Investor.

 

(a)               
If the Investor is an accredited investor as defined in Rule 501(a) of Regulation D, as amended, under the 1933 Act (“Accredited
Investor”), by initialing the appropriate space(s) below, Investor hereby represents that Investor falls into one
of the following categories:

 

_____(i)
a bank as defined in Section 3(a)(2) of the Act, or a savings and loan association or other institution as defined in Section 3(a)(5)(A)
of the Act, whether acting in its individual or fiduciary capacity;

 

_____(ii)
a broker or dealer registered pursuant to Section 15 of the Securities Exchange Act of 1934;

 

_____(iii)
an insurance company as defined in Section 2(13) of the Act;

 

_____(iv)
an investment company registered under the Investment Company Act of 1940 (the “Investment Company Act”);

 

_____(v)a
business development company as defined in Section 2(a)(48) of the Investment Company Act;

 

_____(vi)
a Small Business Investment Company licensed by the U.S. Small Business Administration under Section 301(c) or (d) of the Small
Business Investment Act of 1958, as amended;

 

_____(vii)
a plan established and maintained by a state, its political subdivisions, or any agency or instrumentality of a state or its political
subdivisions, for the benefit of its employees, if such plan has total assets in excess of $5,000,000;

 

_____(viii)an
employee benefit plan within the meaning of Title I of the Employee Retirement Income Security Act of 1974, as amended (“ERISA”),
if either:

 

_____(A)
the investment decision is made by a plan fiduciary, as defined in Section 3(21) of ERISA, which is either a bank, savings
and loan association, insurance company or registered investment adviser,

 

_____(B)
the employee benefit plan has total assets in excess of $5,000,000, or

 

_____(C)
the plan is a self-directed plan with investment decisions made solely by Persons that are Accredited Investors;

 

_____(ix)a
private business development company as defined in Section 202(a)(22) of the Investment Advisers Act of 1940;

 

_____(x)an
organization described in Section 501(c)(3) of the Internal Revenue Code of 1986, as amended (the “Code”), a corporation,
a Massachusetts or similar business trust, or a partnership, in each case, not formed for the specific purpose of making an investment
in the Company, and in each case, with total assets in excess of $5,000,000;

 

 

 

 

    	 	8	 

     

    

 

_____(xi)a
director or executive officer of the Company issuing the Shares being offered or sold, or a director, executive officer, or general
partner of a general partner of that issuer;

 

_____(xii)a
natural person whose individual net worth, or joint net worth with his or her spouse, excluding the value of the person’s
primary residence and any amount of debt secured by his or her primary residence incurred within the past 60 days, at the time
of his or her purchase exceeds $1,000,000;

 

_____(xiii)a
natural person who has an individual income in excess of $200,000 in each of the two most recent years or joint income with that
Person’s spouse in excess of $300,000 in each of those years and has a reasonable expectation of reaching the same income
level in the current year;

 

_____(xiv)a
trust, with total assets in excess of $5,000,000, not formed for the specific purpose of making an investment in the Company whose
purchase of the Securities offered is directed by a sophisticated Person as described in Rule 506(b)(2)(ii) of Regulation D; or

 

_____(xv)an
entity in which all of the equity owners are Accredited Investors.

 

(b)              
If the Investor is not an Accredited Investor as defined above, then by signing below, the Investor acknowledges and agrees
that the Company has provided to the Investor all the information required to be provided to non-accredited investors by Regulation
D, Rule 506, including but not limited to the Company’s public filings (including copies of the Company’s most recent
annual report on Form 10-K, quarterly report on Form 10-Q, and other interim public filings), which contain audited and reviewed
financial statements and other information relating to the Company.

 

4.7.           
No General Advertisement. Investor did not learn of the investment in the Securities as a result of any public advertisement,
article, notice or other communication regarding the Securities published in any newspaper, magazine or similar media or broadcast
over television, radio or internet or presented at any seminar or other general advertisement. Rather, Investor learned of the
investment in the Securities through its prior contact with the Company, its agents and/or its affiliates.

 

4.8.           
Prohibited Transactions. During the last thirty (30) days prior to the date hereof, neither Investor nor any affiliate
of Investor which (x) had knowledge of the transactions contemplated hereby, (y) has or shares discretion relating to Investor’s
investments or trading or information concerning Investor’s investments, including in respect of the Securities, or (z) is
subject to Investor’s review or input concerning such affiliate’s investments or trading (collectively, “Trading
Affiliates”) has, directly or indirectly, effected or agreed to effect any short sale, whether or not against the
box, established any “put equivalent position” (as defined in Rule 16a-1(h) under the 1934 Act) with respect to the
Common Stock, granted any other right (including, without limitation, any put or call option) with respect to the Common Stock
or with respect to any security that includes, relates to or derived any significant part of its value from the Common Stock or
otherwise sought to hedge its position in the Securities (each, a “Prohibited Transaction”). Prior to
the earliest to occur of (i) the date that the Registration Statement (as defined in the Registration Rights Agreement) is declared
effective by the SEC or (ii) the date on which the Registration Statement is required to be declared effective by the SEC under
the terms of the Registration Rights Agreement, Investor shall not, and shall cause its Trading Affiliates not to, engage, directly
or indirectly, in a Prohibited Transaction.

 

4.9.           
Contemporaneous Offering. By signing below, the Investor understands, acknowledges, andagrees that the Company has
another offering of its securities, separate and apart from this Offering, to certain investors (the “Investment Unit
Offering”), whereby the Company is selling Units consisting of shares of its common stock and warrants, subject to
different rights and limitations from those applicable to this Offering.

 

 

 

 

    	 	9	 

     

    

 

5.                 
Conditions to Closing.

 

5.1.           
Conditions to the Investor’s Obligations. The obligation of Investor to purchase the Common Stock at the Closing
is subject to the fulfillment to Investor’s satisfaction, on or prior to the Closing Date, of the following conditions, any
of which may be waived by Investor:

 

(a)               
The representations and warranties made by the Company in Section 3 hereof qualified as to materiality shall be true and
correct at all times prior to and on the Closing Date, except to the extent any such representation or warranty expressly speaks
as of an earlier date, in which case such representation or warranty shall be true and correct as of such earlier date, and, the
representations and warranties made by the Company in Section 3 hereof not qualified as to materiality shall be true and correct
in all material respects at all times prior to and on the Closing Date, except to the extent any such representation or warranty
expressly speaks as of an earlier date, in which case such representation or warranty shall be true and correct in all material
respects as of such earlier date. The Company shall have performed in all material respects all obligations and covenants herein
required to be performed by it on or prior to the Closing Date.

 

(b)              
The Company shall have obtained any and all consents, permits, approvals, registrations and waivers necessary or appropriate
for consummation of the purchase and sale of the Securities and the consummation of the other transactions contemplated by the
Transaction Documents, all of which shall be in full force and effect.

 

(c)               
No judgment, writ, order, injunction, award or decree of or by any court, or judge, justice or magistrate, including any
bankruptcy court or judge, or any order of or by any governmental authority, shall have been issued, and no action or proceeding
shall have been instituted by any governmental authority, enjoining or preventing the consummation of the transactions contemplated
hereby or in the other Transaction Documents.

 

(d)              
No stop order or suspension of trading shall have been imposed by the SEC or any other governmental or regulatory body with
respect to public trading in the Common Stock.

 

5.2.           
Conditions to Obligations of the Company. The Company’s obligation to sell and issue the Common Stock at the
Closing is subject to the fulfillment to the satisfaction of the Company on or prior to the Closing Date of the following conditions,
any of which may be waived by the Company:

 

(a)               
The representations and warranties made by the Investor in Section 4 hereof (the “Investor Representations”),
shall be true and correct in all material respects when made, and shall be true and correct in all material respects on the Closing
Date with the same force and effect as if they had been made on and as of said date. The Investor Representations shall be true
and correct in all respects when made, and shall be true and correct in all respects on the Closing Date with the same force and
effect as if they had been made on and as of said date. The Investor shall have performed in all material respects all obligations
and covenants herein required to be performed by it on or prior to the Closing Date.

 

(b)              
The Investor shall have delivered the Purchase Price to the Company.

 

6.                 
Covenants and Agreements of the Company.

 

6.1.           
Reports. The Company will furnish to the Investor and/or its assignees such information relating to the Company and
any subsidiaries as from time to time may reasonably be requested by the Investor and/or its assignees; provided, however, that
the Company shall not disclose material nonpublic information to the Investor, or to advisors to or representatives of the Investor,
unless prior to disclosure of such information the Company identifies such information as being material nonpublic information
and provides the Investor, such advisors and representatives with the opportunity to accept or refuse to accept such material nonpublic
information for review and any Investor wishing to obtain such information enters into an appropriate confidentiality agreement
with the Company with respect thereto.

 

 

 

    	 	10	 

     

    

 

7.                 
Survival and Indemnification.

 

7.1.           
Survival. The representations, warranties, covenants and agreements contained in this Agreement shall survive the
Closing of the transactions contemplated by this Agreement.

 

7.2.           
Indemnification.

 

(a)            
By the Investor. Investor agrees to indemnify and hold harmless the Company and its affiliates and their respective
directors, officers, employees and agents from and against any and all losses, claims, damages, liabilities and expenses (including
without limitation reasonable attorney fees and disbursements and other expenses incurred in connection with investigating, preparing
or defending any action, claim or proceeding, pending or threatened and the costs of enforcement thereof) (collectively, “Losses”)
to which the Company may become subject as a result of any breach of representation, warranty, covenant or agreement made by or
to be performed on the part of Investor under the Transaction Documents, and will reimburse the Company for all such amounts as
they are incurred by the Company.

 

8.                 
Miscellaneous.

 

8.1.           
Successors and Assigns. This Agreement may not be assigned by a party hereto without the prior written consent of
the Company or the Investor, as applicable, provided, however, that Investor may assign its rights and delegate its duties hereunder
in whole or in part to an affiliate or to a third party acquiring some or all of its Securities in a private transaction without
the prior written consent of the Company, after notice duly given by Investor to the Company, provided, that no such assignment
or obligation shall affect the obligations of Investor hereunder. The provisions of this Agreement shall inure to the benefit of
and be binding upon the respective permitted successors and assigns of the parties. Nothing in this Agreement, express or implied,
is intended to confer upon any party other than the parties hereto or their respective successors and assigns any rights, remedies,
obligations, or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement.

 

8.2.           
Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original,
but all of which together shall constitute one and the same instrument. This Agreement may also be executed and transmitted via
electronic transmission, which shall be deemed an original.

 

8.3.           
Titles and Subtitles. The titles and subtitles used in this Agreement are used for convenience only and are not to
be considered in construing or interpreting this Agreement.

 

8.4.           
Notices. Unless otherwise provided, any notice required or permitted under this Agreement shall be given in writing
and shall be deemed effectively given as hereinafter described (i) if given by personal delivery, then such notice shall be deemed
given upon such delivery, (ii) if given by telex or telecopier, then such notice shall be deemed given upon receipt of confirmation
of complete transmittal, (iii) if given by mail, then such notice shall be deemed given upon the earlier of (A) receipt of such
notice by the recipient or (B) three days after such notice is deposited in first class mail, postage prepaid, and (iv) if given
by an internationally recognized overnight air courier, then such notice shall be deemed given one business day after delivery
to such carrier. All notices shall be addressed to the party to be notified at the address as follows, or at such other address
as such party may designate by ten days’ advance written notice to the other party:

 

If to the Company:

 

Dthera Sciences

9921 Carmel Mountain Road, Suite
118

San Diego, CA 92129

Attention: Edward Cox, CEO

 

 

 

    	 	11	 

     

    

 

With a copy (which shall not
constitute notice) to:

 

Kirton McConkie, PC

50 E. South Temple, Suite 400

Salt Lake City, Utah 84111

Attention: C. Parkinson Lloyd,
Esq.

 

If to the Investor:

 

to the addresses
set forth on the signature page hereto.

 

8.5.           
Expenses. The parties hereto shall pay their own costs and expenses in connection herewith. In the event that legal
proceedings are commenced by any party to this Agreement against another party to this Agreement in connection with this Agreement
or the other Transaction Documents, the party which does not prevail in such proceedings shall pay the reasonable attorneys’
fees and other reasonable out-of-pocket costs and expenses incurred by the prevailing party in such proceedings.

 

8.6.           
Amendments and Waivers. Any term of this Agreement may be amended and the observance of any term of this Agreement
may be waived (either generally or in a particular instance and either retroactively or prospectively), only with the written consent
of the Company and the Investor. 

 

8.7.           
Severability. Any provision of this Agreement that is prohibited or unenforceable in any jurisdiction shall, as to
such jurisdiction, be ineffective to the extent of such prohibition or unenforceability without invalidating the remaining provisions
hereof but shall be interpreted as if it were written so as to be enforceable to the maximum extent permitted by applicable law,
and any such prohibition or unenforceability in any jurisdiction shall not invalidate or render unenforceable such provision in
any other jurisdiction. To the extent permitted by applicable law, the parties hereby waive any provision of law which renders
any provision hereof prohibited or unenforceable in any respect.

 

8.8.           
Entire Agreement. This Agreement, including the other Transaction Documents, constitutes the entire agreement among
the parties hereof with respect to the subject matter hereof and thereof and supersede all prior agreements and understandings,
both oral and written, between the parties with respect to the subject matter hereof and thereof.

 

8.9.           
Further Assurances. The parties shall execute and deliver all such further instruments and documents and take all
such other actions as may reasonably be required to carry out the transactions contemplated hereby and to evidence the fulfillment
of the agreements herein contained.

 

8.10.       
Governing Law; Consent to Jurisdiction; Waiver of Jury Trial. This Agreement shall be governed by, and construed
in accordance with, the internal laws of the State of California without regard to the choice of law principles thereof. Each of
the parties hereto irrevocably submits to the exclusive jurisdiction of the state and federal courts located in San Diego County,
California for the purpose of any suit, action, proceeding or judgment relating to or arising out of this Agreement and the transactions
contemplated hereby. Service of process in connection with any such suit, action or proceeding may be served on each party hereto
anywhere in the world by the same methods as are specified for the giving of notices under this Agreement. Each of the parties
hereto irrevocably consents to the jurisdiction of any such court in any such suit, action or proceeding and to the laying of venue
in such court. Each party hereto irrevocably waives any objection to the laying of venue of any such suit, action or proceeding
brought in such courts and irrevocably waives any claim that any such suit, action or proceeding brought in any such court has
been brought in an inconvenient forum. EACH OF THE PARTIES HERETO WAIVES ANY RIGHT TO REQUEST A TRIAL BY JURY IN ANY LITIGATION
WITH RESPECT TO THIS AGREEMENT AND REPRESENTS THAT COUNSEL HAS BEEN CONSULTED SPECIFICALLY AS TO THIS WAIVER.

 

8.11.       
Company Acceptance. This Agreement is not binding on the Company unless and until the Company executes the signature
page set forth below.

 

 

[Signature page follows.]

 

    	 	12	 

     

    

 

The
undersigned has (have) executed this Investment Unit Purchase Agreement on this _____ day of _____ 2017.

 

The Investor:

 

	 	 	 
	
        Signature
	 	
        Signature of Spouse/Partner
(if applicable)

	 	 	 
	 	 	 
	Individual or Entity Name (and
Title, if applicable) 	 	Name 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	Address	 	Address
	 	 	 
	 	 	 
	Federal Identification or Social
Security No.	 	Federal Identification or Social Security
        No.
	 	 	 
	 	 	 
	State of Domicile/Organization/Incorporation	 	 

 

 

	Additional Information for Notice:	Facsimile:	 
	 	Email:	 

 

 

	Aggregate Purchase Price:	$	 	 
	 	 	 	 	 	 
	Number of Shares:	 	 	 	 

 

	Date:	, 2017	 

 

 

 

    	 	13	 

     

    

 

IN WITNESS WHEREOF,
the Company has executed this Investment Unit Purchase Agreement or caused its duly authorized officer to execute this Agreement
as of the date set forth below.

 

 

	The Company:	DTHERA SCIENCES
	 	 	 
	 	 	 
	 	By:	 
	 	Name:
	 	Title:
	 	 	 
	 	Date of Execution: _______ ___, 2017

 

 

 

 

 

    	 	14	 

     

    

 

EXHIBIT A

 

REPURCHASE RIGHT SCHEDULE

 

The Company's Repurchase
Right will terminate and expire with respect to [one-sixth tranches/the number] of the shares of Common Stock purchased as set
forth below, as follows:

 

(a)               
The Repurchase Right with respect to __________ shares will expire on _____ ___, 2018.

 

(b)              
The Repurchase Right with respect to __________ shares will expire on _____ ___, 2018.

 

(c)               
The Repurchase Right with respect to __________ shares will expire on _____ ___, 2019.

 

(d)              
The Repurchase Right with respect to __________ shares will expire on _____ ___, 2019.

 

(e)               
The Repurchase Right with respect to __________ shares will expire on _____ ___, 2020.

 

(f)               
The Repurchase Right with respect to __________ shares will expire on _____ ___, 2020.

 

(g)               
The Company may exercise the Repurchase Right (as applicable) by paying to the employee any cash paid for the shares of
Common Stock subject to the Repurchase Right and by releasing the employee from any obligation under a promissory note for the
shares of Common Stock subject to the Repurchase Right, or any combination thereof, as applicable.

 

	DTHERA SCIENCES	 	INVESTOR
	 	 	 	 
	 	 	 	 
	By:	 	 	 
	 	 	 
	Name:	 	 	Date: _____ ___, 2017
	 	 	 	 
	Title:	 	 
	 	 	 
	Date: 	________ ___, 2017	 

 

 

 

 

 

 

 

 

    	 	15Exhibit 10.1

 

RESTRICTED COMMON STOCK

 

Granted by

 

Cellectar Biosciences, Inc. (the
“Company”)

 

Under the 2015 Stock Incentive Plan

 

This Restricted Common Stock (the “Grant”)
is and shall be subject in every respect to the provisions of the Company’s 2015 Stock Incentive Plan, as amended from time
to time (the “Plan”), which is incorporated herein by reference and made a part hereof. The holder of this Restricted
Common Stock (the “Holder”) hereby accepts this Grant subject to all the terms and provisions of the Plan and
agrees that (a) in the event of any conflict between the terms hereof and those of the Plan, the latter shall prevail, and (b)
all decisions under and interpretations of the Plan by the Board or the Committee (as each term is defined in the Plan) shall be
final, binding and conclusive upon the Holder and his or her heirs and legal representatives.

 

		1.	Name of Holder: _______________.

 

		2.	Date of Grant: _____________ 2017.

 

		3.	Number of Shares Granted: ______________.

 

		4.	(a)Vesting Schedule.  This Grant shall vest in three equal annual installments beginning on the first anniversary
of the date of grant (each such anniversary shall be considered the “Scheduled Vesting Date” for the installment to
which it applies). With respect to each installment, the Holder must be continuously employed with the Company from the date of
grant through the Scheduled Vesting Date in order to become vested with respect to such installment.

 

(b)       Accelerated
Vesting. Notwithstanding Section 4(a), the unvested portion of the Grant is subject to acceleration and full vesting
prior to a Scheduled Vesting Date if there is an Acceleration Event. As used herein, an “Acceleration Event” shall
mean either of the following events, but only if such event occurs within one (1) year following, or in connection with but prior
to, a Change of Control (as defined in the Plan):

 

(i)       termination
by the Company of the Holder’s employment or service relationship with the Company for any reason other than for Cause (as
defined in the Plan); or

 

(ii)       the
Holder’s resignation as an employee of, or service provider to, the Company, other than for reasons of Disability (as defined
in the Plan) following (x) a significant reduction in the nature or scope of the Holder’s duties, responsibilities, authority
or powers, from the duties, responsibilities, authority or powers exercised by the Holder immediately prior to the Change of Control,
or (y) a reduction in the Holder’s annual base salary (or base fees, as applicable) or benefits as in effect on the date
of the Change of Control, except for across-the-board salary or benefits reductions affecting all similarly situated personnel
of the Company, or (z) a transfer of the Holder from the office of the Company where he is based immediately before the Change
of Control to an office more than twenty-five (25) miles away such office (unless the distance the Holder has to travel to work
is actually shortened as a result of such transfer).

 

     

     

    

 

For purposes of this Section
4, “Company” shall include any surviving entity, in the case of a merger or acquisition in which the Company is
not the surviving entity.

 

		5.	Termination of Employment or Provision of Services for Cause. This Grant shall immediately terminate upon termination
of the Holder’s employment with, or provision of services to, the Company by the Company for Cause and all shares subject
to the Grant, whether or not vested, shall be immediately forfeit to the Company.

 

		6.	Lock-Up Agreement.  The Holder agrees for a period of up to 180 days from the effective date of any registration of
securities of the Company under the Securities Act of 1933, as amended (the “Securities Act”), upon request
of the Company or underwriters managing any underwritten offering of the Company’s securities, not to sell, make any short
sale of, loan, grant any option for the purchase of, or otherwise dispose of any shares issued pursuant to the Grant, without the
prior written consent of the Company and such underwriters.

 

		7.	Tax Withholding. The Company’s obligation to deliver shares pursuant to the Grant shall be subject to the Holder’s
satisfaction of any federal, state and local income and employment tax withholding requirements. Such withholding tax shall be
paid in cash by or on behalf of the Holder.

 

		8.	Notice. Any notice to be given to the Company hereunder shall be deemed sufficient if addressed to the Company and delivered
to the office of the Company, 3301 Agriculture Drive, Madison, WI 53716, attention of the president, or such other address as the
Company may hereafter designate.

 

Any notice to be given to the Holder
hereunder shall be deemed sufficient if addressed to and delivered in person to the Holder at his or her address furnished to the
Company or when deposited in the mail, postage prepaid, addressed to the Holder at such address.

 

IN WITNESS WHEREOF, the parties have executed
this Grant, or caused this Grant to be executed, as of the Date of Grant.

 

CELLECTAR BIOSCIENCES, INC.

 

By: ___________________________

Chad Kolean, VP of Finance/CFO

The undersigned Holder hereby acknowledges receipt of a copy of the Plan and this Grant, and agrees to the terms of this Grant
and the Plan.

 

 

___________________________________

Holder

 

 

    	 	2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00273-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00273-of-00352.parquet"}]]